Format

Send to

Choose Destination
Diabet Med. 2015 Jul;32(7):890-8. doi: 10.1111/dme.12772. Epub 2015 Apr 30.

The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.

Author information

1
Pharmerit International, Rotterdam, The Netherlands.
2
Centre for Health Economics, Swansea University, Monmouth, UK.
3
HEOR, Monmouth, UK.
4
Bristol-Myers Squibb Pharmaceuticals, Uxbridge, UK.
5
AstraZeneca UK, Luton, UK.
6
AstraZeneca, Mölndal, Sweden.
7
Tolley Health Economics, Buxton, UK.
8
Bristol-Myers Squibb, Rueil-Malmaison, France.
9
AstraZeneca, Brussels, Belgium.

Abstract

AIMS:

To assess the cost-effectiveness of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared with a sulfonylurea, when added to metformin for treatment of UK people with Type 2 diabetes mellitus inadequately controlled on metformin alone.

METHODS:

Clinical inputs sourced from a head-to-head randomized controlled trial (RCT) informed the Cardiff diabetes decision model. Risk equations developed from the United Kingdom Prospective Diabetes Study (UKPDS) were used in conjunction with the clinical inputs to predict disease progression and the incidence of micro- and macrovascular complications over a lifetime horizon. Cost and utility data were generated to present the incremental cost-effectiveness ratio (ICER) for both treatment arms, and sensitivity and scenario analyses were conducted to assess the impact of uncertainty on the final model results.

RESULTS:

The dapagliflozin treatment arm was associated with a mean incremental benefit of 0.467 quality-adjusted life years (QALYs) [95% confidence interval (CI): 0.420; 0.665], with an incremental cost of £1246 (95% CI: £613; £1637). This resulted in an ICER point estimate of £2671 per QALY gained. Incremental costs were shown to be insensitive to parameter variation, with only treatment-related weight change having a significant impact on the incremental QALYs. Probabilistic sensitivity analysis determined that dapagliflozin had a 100% probability of being cost-effective at a willingness-to-pay threshold of £20,000 per QALY.

CONCLUSIONS:

Dapagliflozin in combination with metformin was shown to be a cost-effective treatment option compared with sulfonylurea from a UK healthcare perspective for people with Type 2 diabetes mellitus who are inadequately controlled on metformin monotherapy.

PMID:
25817050
DOI:
10.1111/dme.12772
[Indexed for MEDLINE]

Publication types, MeSH terms, Substances

Publication types

MeSH terms

Substances

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center